New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
13:26 EDTAGN, SPPISpectrum regaining rights to bladder cancer drug not a positive, The Street says
Allergan (AGN) returning the rights to bladder cancer drug apaziquone back to Spectrum Pharmaceuticals (SPPI) is not a positive for Spectrum, contends The Street's Adam Feuerstein. Feuerstein says that Spectrum will need to conduct an additional phase III study of the drug and that the company is going to file for FDA approval based on two, separate studies that each failed to hit their primary endpoints with statistical significance. The Fly notes that Spectrum shares are up about 6.9% to $12.75 in early afternoon trading. Reference Link
News For SPPI;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
12:30 EDTAGNGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTAGNActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information
January 20, 2015
10:06 EDTSPPIHigh option volume stocks
Subscribe for More Information
January 13, 2015
14:00 EDTAGNActavis says Allergan deal could close as early as Q1, as late as Q2
Subscribe for More Information
07:39 EDTAGNAmerican Academy of Cosmetic Surgery to hold a meeting
Subscribe for More Information
January 12, 2015
09:37 EDTAGNSupreme Court rejects Allergan appeal on generic Latisse, Bloomberg reports
08:09 EDTAGNActavis and Allergan announce early termination of HSR waiting period
Subscribe for More Information
08:07 EDTAGNActavis, Allergan announce early termination of Hart Scott Rodino waiting period
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use